Iloprost in pulmonary hypertension

References

• Simonneau G, Galie N, Rubin LJ et al. Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol.43(Suppl. 12), S5–S12 (2004).
   PubMed Web of Science ®Google Scholar
• Laliberte K, Arneson C, Jeffs R, Hunt T, Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J. Cardiovasc. Pharmacol.44, 209–214 (2004).
   PubMed Web of Science ®Google Scholar
• Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Evidence-based clinical practice guidelines hypertension: updated ACCP medical therapy for pulmonary arterial. Chest131, 1917–1928 (2007).
   PubMed Web of Science ®Google Scholar
• Olschewski H, Rose F, Schermuly R et al. Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol. Ther.102, 139–153 (2004).
   PubMed Web of Science ®Google Scholar
• Fisher CA, Kappa JR, Sinha AK et al. Comparison of equimolar concentrations of iloprost, prostacyclin and prostaglandin E1, on human platelet function. J. Lab. Clin. Med.109, 184–190 (1987).
   PubMed Web of Science ®Google Scholar
• Stürzebecher CS, Losert W. Effects of iloprost on platelet activation in vitro. In: Prostacyclin and Its Stable Analogue Iloprost. Gryglewski RJ, Stock G (Eds). Springer-Verlag, Berlin, Germany 39–45 (1987).
   Google Scholar
• Wharton J, Davie N, Upton PD, Yacoub MH, Polak JM, Morrell NW. Prostacyclin analoques differentially inhibits growt of distal and proximal human pulmonary smooth muscle cells. Circulation102, 3130–3136 (2000).
   PubMed Web of Science ®Google Scholar
• Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, Tinker A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am. J. Respir. Cell Mol. Biol.26, 194–201 (2002).
   PubMed Web of Science ®Google Scholar
• Orie NN, Fry CH, Clapp LH. Evidence that inward rectifier K+ channels mediate relaxation by the PGI2 receptor agonist cicaprost via a cyclic AMP-independent mechanism. Cardiovasc. Res.69, 107–115 (2006).
   Google Scholar
• Olschewski H, Rose F, Grünig E et al. Cellular pathophysiology and therapy of pulmonary hypertension. J. Lab. Clin. Med.138, 367–377 (2001).
   PubMed Web of Science ®Google Scholar
• Tuder RM, Cool CD, Geraci MW et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med.159, 1925–1932 (1999).
   PubMed Web of Science ®Google Scholar
• Hoshikawa Y, Voelkel NF, Gesell TL et al. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am. J. Respir. Crit. Care Med.164, 314–318 (2001).
   PubMed Web of Science ®Google Scholar
• Shirotani M, Yui Y, Hattori R, Kawai C. U-61,431F, a stable prostacyclin analogue, inhibits the proliferation of bovine vascular smooth muscle cells with little antiproliferative effect on endothelial cells. Prostaglandins41, 97–110 (1991).
   PubMedGoogle Scholar
• Christman BW, McPherson CD, Newman JH et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med.327, 70–75 (1992).
   PubMed Web of Science ®Google Scholar
• Weissmann N, Gerigk B, Kocer O et al. Hypoxia-induced pulmonary hypertension: different impact of iloprost, sildenafil, and nitric oxide. Respir. Med.101, 2125–2132 (2007).
   PubMed Web of Science ®Google Scholar
• Wilkens H, Bauer M, Forestier N et al. Influence of inhaled iloprost on transpulmonary gradient of big endothelin in patients with pulmonary hypertension. Circulation107, 1509–1513 (2003).
   Google Scholar
• Schulz A. Pharmacology of prostanoids. In: Iloprost in Intensive Care Medicine. Ewert R (Ed.). Uni-Med Verlag AG, Bremen, Germany 10–30 (2006).
   Google Scholar
• Moncada S, Gryglewski RJ, Bunting S et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature263, 663–665 (1976).
   PubMed Web of Science ®Google Scholar
• Cowley AJ, Heptinstall S, Hampton JR. Effects of prostacyclin and of the stable prostacyclin analogue ZK36374 on forearm blood flow and blood platelet behaviour in man. Thromb. Haemost.53, 90–94 (1985).
   PubMed Web of Science ®Google Scholar
• Ewert R. The use of iloprost in patients with pulmonary hypertension. In: Iloprost in Intensive Care Medicine. Ewert R (Ed.). Uni-Med Verlag AG, Bremen, Germany 46–73 (2006).
   Google Scholar
• Schermuly RT, Schulz A, Ghofrani HA et al. Pharmacokinetics and metabolism of infused versus inhaled iloprost in isolated rabbit lungs. J. Pharmacol. Exp. Ther.303, 741–745 (2002).
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Schulz A, Ghofrani HA et al. Comparison of pharmacokinetics and vasodilatory effect of nebulized and infused iloprost in experimental pulmonary hypertension: rapid tolerance development. J. Aerosol. Med.19, 353–363 (2006).
   Google Scholar
• Schermuly RT, Pullamsetti SS, Breitenbach SC et al. Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs. Respir. Res.8, 4 (2007).
   PubMedGoogle Scholar
• Smyth EM, Nestor PV, FitzGerald GA. Agonist-dependent phosphorylation of an epitope-tagged human prostacyclin receptor. J. Biol. Chem.271, 33698–33704 (1996).
   Google Scholar
• Kleemann E, Schmehl T, Gessler T, Bakowsky U, Kissel T, Seeger W. Iloprost-containing liposomes for aerosol application in pulmonary arterial hypertension: formulation aspects and stability. Pharm. Res.24, 277–287 (2007).
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Inholte C, Ghofrani HA et al. Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. Respir. Res.6, 76 (2005).
   PubMedGoogle Scholar
• Kaukinen S, Ylitalo P, Pessi T, Vapaatalo H. Hemodynamic effects of iloprost, a prostacyclin analog. Clin. Pharmacol. Ther.36, 464–469 (1984).
   PubMed Web of Science ®Google Scholar
• Groves BM, Badesch DB, Donnellan K et al. Acute hemodynamic effects of iloprost in primary (unexplained) pulmonary hypertension. Sem. Respir. Crit. Care Med.15, 230–237 (1994).
   Web of Science ®Google Scholar
• Scott JP, Higenbottam T, Wallwork J. The acute effect of the synthetic prostacyclin analogue iloprost in primary pulmonary hypertension. Br. J. Clin. Pract.44, 231–234 (1990).
   PubMedGoogle Scholar
• deLaMata J, Gomez-Sanchez MA, Aranzana M, Gomez-Reino JJ. Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. Arthritis Rheum.37, 1528–1533 (1994).
   Google Scholar
• Higenbottam TW, Butt AY, Dinh-Xaun AT, Takao M, Cremona G, Akamine S. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart79, 175–179 (1998).
   PubMed Web of Science ®Google Scholar
• Opitz CF, Wensel R, Bettmann M et al. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur. Heart J.24, 356–365 (2003).
   PubMed Web of Science ®Google Scholar
• Higenbottam TW, Butt AY, McMahon A, Westerbeck R, Sharples L. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart80, 151–155 (1998).
   PubMed Web of Science ®Google Scholar
• Ewert R, Opitz C, Wensel R et al. Iloprost as inhalational and intravenous long-term treatment of patients with primary pulmonary hypertension. Register of the Berlin Study Group for Pulmonary Hypertension. Z. Kardiol.89, 987–999 (2000).
   PubMedGoogle Scholar
• Hoeper MM, Spiekerkoetter E, Westerkamp V, Gatzke R, Fabel H. Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension. Eur. Respir. J.20, 339–343 (2002).
   PubMed Web of Science ®Google Scholar
• Ewert R, Opitz CF, Wensel R, Winkler J, Halank M, Felix SB. Continuous intravenous iloprost to revert treatment failure of first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Clin. Res. Cardiol.96, 211–217 (2007).
   PubMed Web of Science ®Google Scholar
• Bartosik I, Eskilsson J, Scheja A, Akesson A. Intermittent iloprost infusion therapy of pulmonary hypertension in scleroderma – a pilot study. Br. J. Rheumatol.35, 1187–1188 (1996).
   Google Scholar
• Caramaschi P, Volpe A, Tinazzi I, Bambara LM, Carletto A, Biasi D. Does cyclically iloprost infusion prevent severe isolated pulmonary hypertension in systemic sclerosis? Preliminary results. Rheumatol. Int.27, 203–205 (2006).
   PubMed Web of Science ®Google Scholar
• Baysal A, Bilsel S, Bulbul OG et al. Comparison of the usage of intravenous iloprost and nitroglycerin for pulmonary hypertension during valvular heart surgery. Heart. Surg. Forum9, E536–E542 (2006).
   Google Scholar
• Hsu HH, Chen JS, Chen YS et al. Short-term intravenous iloprost for treatment of reperfusion lung oedema after pulmonary thromboendarterectomy. Thorax62, 459–461 (2007).
   Google Scholar
• Halank M, Kolditz M, Opitz C, Hoeffken G, Ewert R. Successful switch from long-term intravenous iloprost to non-invasive combination therapy in idiopathic pulmonary arterial hypertension. Wien. Klin. Wochenschr.118, 54–59 (2006).
   Google Scholar
• Wigley FM, Wise RA, Seibold JR et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann. Intern. Med.120, 199–206 (1996).
   Google Scholar
• Bettoni L, Geri A, Airo P et al. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. Clin. Rheumatol.21, 244–250 (2002).
   PubMed Web of Science ®Google Scholar
• Scorza R, Caronni M, Mascagni B et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud’s phenomenon. A randomized, controlled study. Clin. Exp. Rheumatol.19, 503–508 (2001).
   PubMed Web of Science ®Google Scholar
• Olschewski H, Rohde B, Behr J et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest124, 1294–1304 (2003).
   PubMed Web of Science ®Google Scholar
• Gessler T, Schmehl T, Hoeper MM et al. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. Eur. Respir. J.17, 14–19 (2001).
   PubMed Web of Science ®Google Scholar
• Harris KW, O’Riordan TG, Smaldone GC. Aerosolized iloprost customized for the critically ill. Respir. Care52, 1507–1509 (2007).
   PubMedGoogle Scholar
• Olschewski H, Walmrath D, Schermuly R et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann. Intern. Med.124, 820–824 (1996).
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Olschewski H, Ghofrani HA et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J. Am. Coll. Cardiol.35, 176–182 (2000).
   PubMed Web of Science ®Google Scholar
• Hallioglu O, Dilber E, Celiker A. Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease. Am. J. Cardiol.92, 1007–1009 (2003).
   PubMed Web of Science ®Google Scholar
• Rimensberger PC, Spahr-Schopfer I, Berner M et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation103, 544–548 (2001).
   PubMed Web of Science ®Google Scholar
• Bratel T, Lagerstrand L, Brodin LA, Nowak J, Randmaa I. Ventilation/perfusion ratios in pulmonary arterial hypertension: effects of IV and inhaled prostacyclin derivatives. Chest128(6 Suppl.), S615–S616 (2005).
   Google Scholar
• Bratel T, Lagerstrand L, Brodin LA, Nowak J, Randmaa I. Ventilation-perfusion relationships in pulmonary arterial hypertension: effect of intravenous and inhaled prostacyclin treatment. Respir. Physiol. Neurobiol.158, 59–69 (2007).
   PubMedGoogle Scholar
• Leuchte HH, Schwaiblmair M, Baumgartner RA, Neurohr CF, Kolbe T, Behr J. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest125, 580–586 (2004).
   PubMed Web of Science ®Google Scholar
• Ulrich S, Fischler M, Speich R, Popov V, Maggiorini M. Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties. Chest130, 841–846 (2006).
   PubMed Web of Science ®Google Scholar
• Yurtseven N, Karaca P, Uysal G et al. A comparison of the acute hemodynamic effects of inhaled nitroglycerin and iloprost in patients with pulmonary hypertension undergoing mitral valve surgery. Ann. Thorac. Cardiovasc. Surg.12, 319–323 (2006).
   PubMedGoogle Scholar
• Ercan ZS, Türker RK. Possible β-adrenoceptor modulating effect of ZK 36 374 a stable analogue of carbacyclin. Prostaglandins Leukot. Med.15, 45–52 (1984).
   PubMedGoogle Scholar
• Kramm T, Eberle B, Krummenauer F, Guth S, Oelert H, Mayer E. Inhaled iloprost in patients with chronic thromboembolic pulmonary hypertension: effects before and after pulmonary thromboendarterectomy. Ann. Thorac. Surg.76, 711–718 (2003).
   PubMed Web of Science ®Google Scholar
• Krug S, Hammerschmidt S, Pankau H, Wirtz H, Seyfarth HJ. Acute improved hemodynamics following inhaled iloprost in chronic thromboembolic pulmonary hypertension. Respiration76(2), 154–159 (2008).
   PubMed Web of Science ®Google Scholar
• Kramm T, Eberle B, Guth S, Mayer E. Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy. Eur. J. Cardiothorac. Surg.28, 882–888 (2005).
   PubMed Web of Science ®Google Scholar
• Sablotzki A, Czeslick E, Schubert S et al. Iloprost improves hemodynamics in patients with severe chronic cardiac failure and secondary pulmonary hypertension. Can. J. Anaesth.49, 1076–1080 (2002).
   PubMedGoogle Scholar
• Braun S, Schrötter H, Schmeisser A, Strasser RH. Evaluation of pulmonary vascular response to inhaled iloprost in heart transplant candidates with pulmonary venous hypertension. Int. J. Cardiol.115, 67–72 (2007).
   PubMedGoogle Scholar
• Sablotzki A, Hentschel T, Hofmann S, Simm A, Mühling J, Czeslick E. Inhaled aerosolized iloprost in the evaluation of heart transplant candidates – experiences with 45 cases. J. Clin. Anesth.18, 108–113 (2006).
   PubMedGoogle Scholar
• Ghofrani HA, Rose F, Schermuly RT et al. Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit. Care Med.30, 2489–2492 (2002).
   PubMed Web of Science ®Google Scholar
• Wilkens H, Guth A, König J et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation104, 1218–1222 (2001).
   PubMed Web of Science ®Google Scholar
• Wensel R, Opitz CF, Ewert R, Bruch L, Kleber FX. Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension. Circulation101, 2388–2392 (2000).
   PubMed Web of Science ®Google Scholar
• Blumberg FC, Riegger GA, Pfeifer M. Hemodynamic effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise. Chest121, 1566–1571 (2002).
   PubMed Web of Science ®Google Scholar
• Wonisch M, Fruhwald FM, Maier R et al. Continuous haemodynamic monitoring during exercise in patients with pulmonary hypertension. Int. J. Cardiol.101, 415–420 (2005).
   PubMedGoogle Scholar
• Fruhwald FM, Kjellström B, Perthold W et al. Continuous hemodynamic monitoring in pulmonary hypertensive patients treated with inhaled iloprost. Chest124, 351–359 (2003).
   PubMed Web of Science ®Google Scholar
• Schenk P, Petkov V, Madl C et al. Aerosolized iloprost therapy could not replace long-term IV epoprostenol (prostacyclin) administration in severe pulmonary hypertension. Chest119, 296–300 (2001).
   PubMedGoogle Scholar
• Petkov V, Ziesche R, Mosgoeller W et al. Aerosolized iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment. Thorax56, 734–736 (2001).
   PubMed Web of Science ®Google Scholar
• Reichenberger F, Mainwood A, Doughty N, Fineberg A, Morrell NW, Pepke-Zaba J. Effects of nebulised iloprost on pulmonary function and gas exchange in severe pulmonary hypertension. Respir. Med.101, 217–222 (2007).
   PubMed Web of Science ®Google Scholar
• Emmel M, Keuth B, Schickendantz S. Paradoxical increase of pulmonary vascular resistance during testing of inhaled iloprost. Heart90, E2 (2004).
   Google Scholar
• Hoeper MM, Schwarze M, Ehlerding S et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N. Engl. J. Med.342, 1866–1870 (2000).
   PubMed Web of Science ®Google Scholar
• Ewert R, Wensel R, Opitz CF. Aerosolized iloprost for primary pulmonary hypertension. N. Engl. J. Med.343, 1421–1422 (2000).
   PubMed Web of Science ®Google Scholar
• Ewert R, Opitz C, Wensel R et al. Iloprost as inhalational and intravenous long-term treatment of patients with primary pulmonary hypertension. Register of the Berlin Study Group for Pulmonary Hypertension. Z. Kardiol.89, 987–999 (2000).
   PubMedGoogle Scholar
• Olschewski H, Simonneau G, Galiè N et al. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med.347, 322–329 (2002).
   PubMed Web of Science ®Google Scholar
• Olschewski H, Hoeper MM, Behr J et al. Safety, dosing, and clinical benefit of 2-years therapy with inhaled iloprost. Proc. Am. Thorac. Soc.2, A200 (2005).
   Google Scholar
• Opitz CF, Wensel R, Winkler J et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur. Heart J.26, 1895–1902 (2005).
   PubMed Web of Science ®Google Scholar
• Machherndl S, Kneussl M, Baumgartner H et al. Long-term treatment of pulmonary hypertension with aerosolized iloprost. Eur. Respir. J.17, 8–13 (2001).
   PubMed Web of Science ®Google Scholar
• Higenbottam T, Siddons T. Trials of inhaled iloprost and other new vasodilating prostaglandins. Eur. Respir. J.17, 6–7 (2001).
   Google Scholar
• Galiè N. Do we need controlled clinical trials in pulmonary arterial hypertension? Eur. Respir. J.17, 1–3 (2001).
   Google Scholar
• Hoeper MM. Long-term treatment of pulmonary hypertension with aerosolized iloprost. Eur. Respir. J.17, 1334–1335 (2001).
   Google Scholar
• Saba T, Peacock AJ. Long-term treatment of pulmonary hypertension with aerosolized iloprost. Eur. Respir. J.18, 247 (2001).
   Google Scholar
• Olschewski H, Ghofrani HA, Schmehl T et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann. Intern. Med.132, 435–443 (2000).
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur. Respir. J.22, 330–334 (2003).
   PubMed Web of Science ®Google Scholar
• Seyfarth HJ, Pankau H, Hammerschmidt S, Schauer J, Wirtz H, Winkler J. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy. Chest128, 709–713 (2005).
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Rose F, Schermuly RT et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J. Am. Coll. Cardiol.42, 158–164 (2003).
   PubMed Web of Science ®Google Scholar
• Durongpisitkul K, Jakrapanichakul D, Laohaprasitiporn D, Soongswang J, Chanthong P, Nana A. Combination therapy of prostacyclin for pulmonary hypertension in congenital heart disease. J. Med. Assoc. Thai.88(Suppl. 8), S60–S65 (2005).
   Google Scholar
• Beyer S, Speich R, Fischler M, Maggiorini M, Ulrich S. Long-term experience with oral or inhaled vasodilator combination therapy in patients with pulmonary hypertension. Swiss Med. Wkly136, 114–118 (2006).
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Seyfarth HJ, Hoeffken G et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur. Respir. J.30(6), 1096–1102 (2007).
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Leuchte H, Halank M et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J.28, 691–694 (2006).
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Oudiz RJ, Frost A et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.174, 1257–1263 (2006).
   PubMed Web of Science ®Google Scholar
• Dandel M, Kemper D, Weng Y et al. Primary pulmonary hypertension: survival benefits of therapy with prostacyclin analogs and transplantation. Transplant Proc.35, 2117–2120 (2003).
   Google Scholar
• Ewert R, Wensel R, Opitz C et al. Prognosis in patients with primary pulmonary hypertension awaiting lung transplantation. Transplant Proc.33, 3574–3575 (2001).
   Google Scholar
• Dandel M, Lehmkuhl HB, Mulahasanovic S et al. Survival of patients with idiopathic pulmonary arterial hypertension after listing for transplantation: impact of iloprost and bosentan treatment. J. Heart Lung Transplant.26, 898–906 (2007).
   PubMed Web of Science ®Google Scholar
• Leuchte HH, Behr J. Iloprost for idiopathic pulmonary arterial hypertension. Expert Rev. Cardiovasc. Ther.3, 215–223 (2005).
   PubMedGoogle Scholar
• Strauss WL, Edelman JD. Prostanoid therapy for pulmonary arterial hypertension. Clin. Chest Med.28, 127–142 (2007).
   PubMedGoogle Scholar
• Olschewski H, Rose F, Schermuly R et al. Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol. Ther.102, 139–153 (2004).
   PubMed Web of Science ®Google Scholar
• Goldsmith DR, Wagstaff AJ. Inhaled iloprost: in primary pulmonary hypertension. Drugs64, 763–773 (2004).
   PubMedGoogle Scholar
• Hsu HH, Rubin LJ. Iloprost inhalation solution for the treatment of pulmonary arterial hypertension. Expert Opin. Pharmacother.6, 1921–1930 (2005).
   PubMed Web of Science ®Google Scholar
• Lowson SM. Inhaled alternatives to nitric oxide. Crit. Care Med.33(Suppl. 3), S188–S195 (2005).
   Google Scholar
• Siobal M. Aerosolized prostacyclins. Respir. Care49, 640–652 (2004).
   PubMedGoogle Scholar
• Baker SE, Hockman RH. Inhaled iloprost in pulmonary arterial hypertension. Ann. Pharmacother.39, 1265–1274 (2005).
   PubMedGoogle Scholar
• Snow JL, Kawut SM. Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy. Clin. Chest Med.28, 75–89 (2007).
   Google Scholar
• Mok MY, Tse HF, Lau CS. Pulmonary hypertension secondary to systemic lupus erythematosus: prolonged survival following treatment with intermittent low dose iloprost. Lupus8, 328–331 (1998).
   Google Scholar
• Vegh J, Soos G, Csipo I et al. Pulmonary arterial hypertension in mixed connective tissue disease: successful treatment with Iloprost. Rheumatol. Int.26, 264–269 (2006).
   Google Scholar
• Halank M, Rubens C, Ewert R, Hoffken G, Braun J. Severe precapillary pulmonary hypertension in possible antiphospholipid syndrome – partially successful long-term therapy with continuous intravenous iloprost administration. A case report with discussion of new treatment methods. Z. Rheumatol.59, 334–342 (2000).
   Google Scholar
• Halank M, Kolditz M, Miehlke S, Schiemanck S, Schmeisser A, Hoeffken G. Combination therapy for portopulmonary hypertension with intravenous iloprost and oral bosentan. Wien. Med. Wochenschr.155, 376–380 (2005).
   PubMedGoogle Scholar
• Minder S, Fischler M, Muellhaupt B et al. Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension. Eur. Respir. J.24, 703–707 (2004).
   PubMed Web of Science ®Google Scholar
• Theodoraki K, Tsiapras D, Tsourelis L et al. Inhaled iloprost in eight heart transplant recipients presenting with post-bypass acute right ventricular dysfunction. Acta Anaesthesiol. Scand.50, 1213–1217 (2006).
   PubMedGoogle Scholar
• Winterhalter M, Simon A, Fischer S et al. Inhaled iloprost in lung transplantation: can it avoid extracorporeal circulation in patients with severe pulmonary hypertension? J. Cardiothorac. Vasc. Anesth.20, 716–718 (2006).
   PubMedGoogle Scholar
• Wittwer T, Franke U, Wahlers T. Impact of aerosolized prostacyclin analog for severe pulmonary hypertension in thoracic organ transplantation. J. Thorac. Cardiovasc. Surg.124, 211–213 (2002).
   PubMedGoogle Scholar
• Müller M, Scholz S, Kwapisz M, Akintürk H, Thul J, Hempelmann G. Use of inhaled iloprost in a case of pulmonary hypertension during pediatric congenital heart surgery. Anesthesiology99, 743–744 (2003).
   PubMedGoogle Scholar
• Rex S, Busch T, Vettelschoss M, de Rossi L, Rossaint R, Buhre W. Intraoperative management of severe pulmonary hypertension during cardiac surgery with inhaled iloprost. Anesthesiology99, 745–747 (2003).
   PubMedGoogle Scholar
• Langer F, Wendler O, Wilhelm W, Tscholl D, Schäfers HJ. Treatment of a case of acute right heart failure by inhalation of iloprost, a long-acting prostacyclin analogue. Eur. J. Anaesthesiol.18, 770–773 (2001).
   PubMedGoogle Scholar
• Olschewski H, Ghofrani HA, Walmrath D et al. Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost. Intensive Care Med.24, 631–634 (1998).
   PubMed Web of Science ®Google Scholar
• Alp S, Schlottmann R, Bauer TT, Schmidt WE, Bastian A. Long-time survival with HIV-related pulmonary arterial hypertension: a case report. AIDS17, 1714–1715 (2003).
   PubMed Web of Science ®Google Scholar
• De Luca D, Zecca E, Piastra M, Romagnoli C. Iloprost as ‘rescue’ therapy for pulmonary hypertension of the neonate. Paediatr. Anaesth.17, 394–395 (2007).
   PubMed Web of Science ®Google Scholar
• Chotigeat U, Jaratwashirakul S. Inhaled iloprost for severe persistent pulmonary hypertension of the newborn. J. Med. Assoc. Thai.90, 167–170 (2007).
   PubMedGoogle Scholar
• Eifinger F, Sreeram N, Mehler K, Huenseler C, Kribs A, Roth B. Aerosolized iloprost in the treatment of pulmonary hypertension in extremely preterm infants: a pilot study. Klin. Padiatr.220(2), 66–69 (2008).
   PubMed Web of Science ®Google Scholar
• Launay D, Hachulla E, Hatron PY et al. Aerosolized iloprost in CREST syndrome related pulmonary hypertension. J. Rheumatol.28, 2252–2256 (2001).
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Friese G, Discher T et al. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur. Respir. J.23, 321–326 (2004).
   PubMed Web of Science ®Google Scholar
• Olschewski H, Ghofrani HA, Walmrath D et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am. J. Respir. Crit. Care Med.160, 600–607 (1999).
   PubMed Web of Science ®Google Scholar
• Leuchte HH, Baumgartner RA, Behr J. Treatment of severe pulmonary hypertension with inhaled iloprost. Ann. Intern. Med.139, 306 (2003).
   PubMed Web of Science ®Google Scholar
• Roig Figueroa V, Herrero Pérez A, de la Torre Ferrera N, Hernández García E, Aller Alvarez JL, Para Cabello J. Iloprost for chronic thromboembolic pulmonary hypertension. Arch. Bronconeumol.40, 326–328 (2004).
   PubMedGoogle Scholar
• Fruhwald FM, Kjellström B, Perthold W, Wonisch M, Maier R, Klein W. Hemodynamic observations in two pulmonary hypertensive patients changing treatment from inhaled iloprost to the oral endothelin-antagonist bosentan. J. Heart Lung Transplant.24, 631–634 (2005).
   PubMedGoogle Scholar
• Mereles D, Ewert R, Lodziewski S et al. Effect of inhaled iloprost during off-medication time in patients with pulmonary arterial hypertension. Respiration74, 498–502 (2007).
   PubMedGoogle Scholar
• Ahmadi-Simab K, Lamprecht P, Gross WL. Successful therapy of bosentan-refractory pulmonary arterial hypertension (PAH) with inhalative iloprost. Clin. Exp. Rheumatol.23, 402–403 (2005).
   PubMedGoogle Scholar
• Okyay K, Cemri M, Boyac B, Yalcn R, Cengel A. Use of long-term combined therapy with inhaled iloprost and oral sildenafil in an adult patient with eisenmenger syndrome. Cardiol. Rev.13, 312–314 (2005).
   PubMedGoogle Scholar
• Molnar C, Alber H, Colleselli D, Vogel W, Kähler CM. Successful switch from inhalative iloprost to oral bosentan in portopulmonary hypertension associated with liver cirrhosis. Wien. Klin. Wochenschr.116, 627–630 (2004).
   PubMed Web of Science ®Google Scholar
• Isa R, Castro P, Martínez A. Aerosolized iloprost combined with a phosphodiesterase inhibitor in the treatment of primary pulmonary hypertension. Rev. Med. Chil.132, 353–356 (2004).
   PubMedGoogle Scholar
• Onen ZP, Akkoca Yildiz O, Eris Gülbay B, Karabiyikoglu G. Inhaled iloprost as a long-term additional therapy to oral sildenafil in severe idiopathic pulmonary arterial hypertension. Tuberk. Toraks.54, 177–181 (2006).
   PubMedGoogle Scholar
• Loureiro MJ, Cotrim C, Simoes O, Miranda R, Cordeiro P, Carrageta M. Acute hemodynamic effect of inhaled iloprost in pulmonary artery hypertension evaluated with echocardiography. Cardiovasc. Ultrasound5, 41 (2007).
   PubMedGoogle Scholar